Repligen | RGEN - Assets


Repligen reported $2.93B in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Agilent USD 13.97B 902M Jun/2026
Align Technology USD 6.52B 103.03M Sep/2026
Bio Techne USD 2.64B 50.09M Sep/2026
BioMarin Pharmaceutical USD 11.57B 154.21M Sep/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Bruker USD 5.83B 224.6M Sep/2026
Charles River Laboratories USD 7.45B 80.64M Sep/2026
Danaher USD 93.28B 914M Sep/2026
Dentsply International USD 5.19B 14M Sep/2026
General Electric Aerospace USD 127.2B 477M Sep/2026
Henry Schein USD 11.51B 129M Sep/2026
Illumina USD 6.81B 162M Sep/2026
IQVIA Holdings USD 30.47B 593M Sep/2026
Mettler Toledo International USD 3.7B 24.53M Sep/2026
Myriad Genetics USD 638.9M 34.8M Jun/2026
OraSure Technologies USD 360.55M 18.62M Jun/2026
Pacific Biosciences Of California USD 721.1M 30.75M Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
Repligen USD 2.93B 23.77M Sep/2026
Revvity USD 11.49B 555.49M Sep/2026
Standard Biotools USD 635.33M 8.11M Sep/2026
Thermo Fisher Scientific USD 114.23B 1.06B Sep/2026
Waters USD 24.12B 636M Sep/2026
West Pharmaceutical Services USD 4.06B 15.7M Sep/2026